Published in

Wiley, British Journal of Clinical Pharmacology, 6(75), p. 1545-1547, 2013

DOI: 10.1111/bcp.12038

Links

Tools

Export citation

Search in Google Scholar

The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations

Journal article published in 2013 by Laure Elens ORCID, Dennis A. Hesselink, Ron H. N. van Schaik, Teun van Gelder
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The cytochrome P450 (CYP) 3A4*22 allelic status influences the pharmacokinetics of tacrolimus independently of an individual's CYP3A5 genotype. In their recent publication, Passey et al described an algorithm that predicts tacrolimus apparent clearance (CL/F) by taking into account the age and CYP3A5 genotype of a patient, time after kidney transplantation, whether the transplantation was performed at a steroid-sparing center or not and whether the patient was treated with a calcium channel blocker (CCB). However, as the effect of the CYP3A4*22 allele was only recently reported, these authors did not consider this variable as a potential predictive factor for tacrolimus CL/F.